Portfolio Lab

Novo Nordisk A S

  • Stock
  • Ticker NVO
  • ISIN US6701002056
  • NYSE
  • US listing in dollars (ADR)

Health care · Pharmaceuticals · Denmark

$37.82 −2.70%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Novo Nordisk A S since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

NVOGlobal equities (VT)

$10,000 grew to $29,005. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −74.7% in 03/2026, measured from the peak in 06/2024. The old peak has not been reached again yet.

1-year return
−16.7%
5-year return p.a.
−5.8%
10-year return p.a.
+11.2%
Volatility p.a.
29.7%
Largest decline
−74.7%

Financial statements

Amounts in DKK millions from the company's annual financial reports, earnings per share in DKK per ordinary share

Fiscal year202020212022202320242025
Income statement
Revenue126,946140,800176,954232,261290,403309,064
Gross profit106,014117,142148,506196,496245,881250,276
Operating income54,12658,64474,809102,574128,339127,658
Net income42,13847,75755,52583,683100,988102,434
Earnings per share18.0120.7424.4418.6222.6323.03
Balance sheet
Total assets144,922194,508241,257314,486465,795542,902
Liabilities81,597123,762157,771207,925322,309348,855
Equity63,32570,74683,486106,561143,486194,047
Cash12,22610,71912,65314,39215,65526,464
Long-term debt2,89712,96124,31820,52889,674118,941
Cash flow
Operating cash flow51,95155,00078,887108,908120,968119,102
Capital expenditure-5,825-6,335-12,146-25,806-47,164-60,140
Free cash flow46,12648,66566,74183,10273,80458,962

Annual returns

Best year 2021 at +63.5%, weakest 2025 at −39.3%. 6 of 9 full years were positive. * partial year.

Key metrics

Key figures as of 21 Nov 2026 from the company's latest annual financial report, amounts converted to US dollars at the ECB reference rate. Valuation and market cap appear only where price and earnings per share reliably refer to the same share.

Valuation

Market cap
€152bn
Market cap in trading currency
$168bn
Enterprise value
$183bn
P/E
11.1
P/S
3.69
P/B
5.88
EV/Sales
4.03
EV/EBITDA
–
Earnings yield
9.0%
FCF yield
5.2%

Results (latest fiscal year)

Revenue
$45.4bn
Gross profit
$36.8bn
EBITDA
–
Net income
$15.1bn
Earnings per share
$3.39
Revenue growth
+6.4%
Earnings growth
+1.4%

Profitability

Gross margin
81.0%
Operating margin
41.3%
Net margin
33.1%
Return on equity
60.7%
Return on assets
18.9%

Balance sheet and cash flow

Cash
$3.89bn
Financial debt
$19.3bn
Debt/equity %
67
Current ratio
0.80
Book value per share
$6.42
Operating cash flow
$17.5bn
Free cash flow
$8.67bn

Dividend

Dividend yield
4.75%
Dividend (12 months)
$1.80
Yield (12 months)
4.75%
Payout ratio
51%
Ex-dividend date
17 Aug 2026

Shares and trading

Shares outstanding
4.44bn
Volume
12.7m
Avg. volume 3 months
12.6m
Relative volume
1.0

Price and technicals

Price
$37.82
1 day
−2.7%
52-week high
$63.98
52-week low
$35.29
Distance to 52-week high
−40.9%
Distance to 52-week low
+7.2%
Distance to 50-day line
−4.5%
Distance to 200-day line
−11.8%
RSI (14)
38
Volatility 1M
35.4%

Performance

1 week
−9.2%
1 month
−4.1%
3 months
−19.4%
6 months
−15.9%
YTD
−25.7%
1 year
−22.8%

Dates

Fiscal year end
31 Dec 2025

Frequently asked questions

How has NVO performed since 11/2016?

$10,000 grew to $29,005 by 20 Nov 2026, which is +11.2% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is NVO?

Volatility was 29.7% per year, measured on monthly returns. The largest decline from a peak was −74.7%, with the low in 03/2026.

How does NVO compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, NVO returned +11.2% at 29.7%. The correlation of monthly returns was 0.28; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Why does this page show a US listing?

The figures use the stock's depositary receipt (ADR) traded in the US. On individual days its path differs slightly from the price on the home exchange.

Not investment advice. Key figures and financial statements calculated from the company's annual financial reports, without guarantee; key figures converted to US dollars at the ECB reference rate, statements in the currency of the report.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Novo Nordisk A S (NVO): Return and risk | Portfolio Lab